"More than 21,500 Canadians will be diagnosed with colorectal cancer this year and most of them will not have exhibited any symptoms. The most effective method for prevention and early detection of colorectal cancer is through widespread screening of individuals," said Barry D. Stein, President of the Colorectal Cancer Association of Canada. "A patient-friendly blood test like ColonSentry(TM) is welcomed and can certainly contribute to increased compliance with screening programs. This will facilitate earlier detection and treatment of the disease, resulting in improved outcomes for patients with colorectal cancer."
"Ideally, colorectal cancer screening should proceed in a programmatic fashion that begins with risk stratification based on the results from an initial test and then continues with proper follow up based on findings," said Dr. Bernard Levin, an internationally recognized expert in colorectal cancer screening and Chair of the Company's Colorectal Cancer Clinical Advisory Board. "As the initial test, the convenience of a blood test to assess current risk could encourage more individuals to undergo screening, leading to earlier detection of colorectal cancer thereby reducing suffering and death."
"More than 1.5 million people in the GTA meet the eligibility
guidelines for colorectal cancer screening, making this an ideal location
for the initial launch of ColonSentry(TM). We are building our commercial
organization and look forward to subsequent planned launches of
ColonSentry(TM) in Asia, the United States and Europe," said Dr. Heiner
Dreismann, interim CEO and Lead Director of GeneNews. "Achieving this most
significant milestone well on target reflects the deep commitment of the
entire GeneNews staff and the timely d
|SOURCE GeneNews Limited|
Copyright©2008 PR Newswire.
All rights reserved